Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry
Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry
复制标题
DOI：
10.1002/ejhf.964
复制
发表时间：
2018-01-01
影响因子：
18.2
通讯作者：
Tavazzi, Luigi
中科院分区：
文献类型：
--
作者：
Canepa, Marco;Straburzynska-Migaj, Ewa;Tavazzi, Luigi
目的描述2011年5月至2013年4月在欧洲登记的慢性阻塞性肺疾病(COPD)合并慢性阻塞性肺疾病(COPD)的住院(HHF)和慢性(CHF)心力衰竭患者的特征和1年预后。方法与结果总体上，1334/6920(19.3%)HHF患者和1322/9409(14.1%)CHF患者被诊断为COPD。在这两组患者中，COPD患者年龄较大，男性较多，临床表现较差，合并疾病的患病率较高。在HHF患者中，非COPD患者出院时使用心力衰竭(HF)药物的增加幅度大于COPD患者：血管紧张素转换酶抑制剂(+13.7%比+7.2%)、β-受体阻滞剂(+20.6%比+11.8%)和盐皮质激素受体拮抗剂(+20.9%比+17.3%)，从而扩大了入院时两组之间已经存在的心衰治疗的差距。在CHF患者中，两组患者在登记访问后使用这些药物的情况相似，使用β-受体阻滞剂的患者与非COPD患者相比，差异有统计学意义(89.8%比81.6%，P
Aims To describe the characteristics and assess the 1-year outcomes of hospitalized (HHF) and chronic (CHF) heart failure patients with chronic obstructive pulmonary disease (COPD) enrolled in a large European registry between May 2011 and April 2013.Methods and results Overall, 1334/6920 (19.3%) HHF patients and 1322/9409 (14.1%) CHF patients were diagnosed with COPD. In both groups, patients with COPD were older, more frequently men, had a worse clinical presentation and a higher prevalence of co-morbidities. In HHF, the increase in the use of heart failure (HF) medications at hospital discharge was greater in non-COPD than in COPD for angiotensin-converting enzyme inhibitors (+13.7% vs. +7.2%), beta-blockers (+20.6% vs. +11.8%) and mineralocorticoid receptor antagonists (+20.9% vs. +17.3%), thus widening the gap in HF treatment already existing between the two groups at admission. In CHF patients, there was a similar increase in the use of these medications after enrollment visit in the two groups, leaving a significant difference of 8.2% for beta-blockers in favour of non-COPD patients (89.8% vs. 81.6%, P